GlassScriptPhysician profile
Francis C Yu
NPI 1184651283
$8,066.98
in general payments reported to CMS, 2019-2025
26 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $825 · 2021: $1,113 · 2022: $1,274 · 2023: $1,568 · 2024: $1,203 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,207 · Consulting Fee: $24.36 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,206.80 |
| Consulting Fee | $24.36 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,417.21 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,008.90 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $744.57 | 2020-2025 | Hyqvia, Takhzyro, Cuvitru |
| Regeneron Healthcare Solutions, INC. | $653.88 | 2019-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $636.30 | 2021-2025 | Orladeyo |
| Astrazeneca Pharmaceuticals LP | $567.99 | 2019-2025 | Fasenra, Tezspire |
| Csl Behring | $448.88 | 2020-2025 | Hizentra, Andembry, Haegarda |
| Grifols USA, LLC | $441.75 | 2020-2025 | Xembify, Gamunex-C |
| Novartis Pharmaceuticals Corporation | $433.41 | 2019-2025 | |
| Pfizer INC. | $368.55 | 2019-2023 | |
| Genentech USA, INC. | $211.40 | 2021-2024 | Xolair |
| Pharming Healthcare, INC. | $200.15 | 2019-2024 | Ruconest |
| Alk-Abello, INC | $196.29 | 2019-2025 | Ragwitek, Odactra, Grastek |
| Ionis Pharmaceuticals, INC. | $138.95 | 2025 | Dawnzera |
| Shire North American Group INC | $105.18 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst Pharmaceuticals, INC. | $100.22 | 2020 | |
| Amgen INC. | $83.37 | 2022-2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $61.85 | 2025 | Neffy |
| Phadia US INC. | $52.57 | 2022-2024 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.45 | 2021-2022 | |
| Blueprint Medicines Corporation | $32.40 | 2023 | Ayvakit |
| Cycle Pharmaceuticals INC | $27.28 | 2025 | Sajazir |
| Optinose US, INC. | $24.62 | 2025 | |
| Adma Biomanufacturing LLC | $24.36 | 2025 | |
| Merck Sharp & Dohme LLC | $23.12 | 2023 | |
| Incyte Corporation | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.